WHAT WE’RE BUILDING
Hormone-Free & Copper-Free
A new female birth control device designed to be highly effective, long-acting and side-effect-free.
THE STANDARD OF BIRTH CONTROL TODAY
The birth control pill was developed in the 1950s.
The birth control pill was FDA approved in 1960. All hormonal methods use the same mechanisms of action as “the pill,” and they can cause the same side effects.
The first copper IUD was FDA approved in 1984.
The first hormonal IUD was approved in 2000.
Despite available birth control options in the US, the unintended pregnancy rate dropped by only 1.7% between 2010 and 2019.
Half of pregnancies are unplanned.
In the US, 27% of pregnancies are mistimed/wanted later, and 18% of pregnancies are unwanted/not wanted at all.
36% of women in the US report they have experienced at least 1 unplanned pregnancy.
30% of US maternal deaths result from unplanned pregnancies.
In 2010, the US government spent $21 billion on the births, abortions, and miscarriages that resulted from unplanned pregnancies.
Available birth control options can cause unwanted side effects.
All highly effective and reversible methods use hormones or copper. Hormones and copper can cause side effects, such as changes in menstrual bleeding. IUDs and implants are associated with additional risks.
50% of women stop using their birth control because they are unhappy with or cannot tolerate the side effects. Changes in menstrual bleeding is the most common reason why women stop or switch their birth control method.
HOW WE’RE DIFFERENT
Bridging The Gap Between IUDs and Barrier Methods
Existing birth control methods do not meet the needs of most women today. We’re pioneering a new class of long-acting barrier contraception.
OUR SOLUTION
A Long-Acting Device
A birth control device for women that is highly effective, long lasting, hormone-free, copper-free, and not intrauterine (in the uterus)
OUR MISSION
Innovating For All
To offer more acceptable and affordable birth control options for all women to help them gain full control over their family planning
COLLABORATIVE AT OUR CORE
Competitive Scientific & Entrepreneurial Programs
WHAT WE’VE BEEN UP TO
Company Updates
-
![]()
$100K MassVentures START Grant
August 2026
Venova Technologies selected for a SBIR Targeted Technologies (START) Grant for Massachusetts-based startups from MassVentures, a venture capital firm supporting seed-stage, deep tech startups.
-
![]()
$2.23M NIH SBIR Phase II Grant
July 2025
Venova Technologies awarded a $2.23M SBIR Phase II grant to accelerate the preclinical development of the company’s cervical barrier device.
-
![]()
Capital Readiness Program
April 2025
Our CEO and COO/CFO participated in the Science Center’s competitive week-long due diligence deep dive for healthtech founders.
-
![]()
Women Leading The Future Keynote
March 2025
Our CEO gave a keynote and participated on a panel at LabCentral & J&J’s International Women’s Day celebration.
-
![]()
$380K NIH SBIR Phase I Grant
September 2024
Venova Technologies received their second SBIR/STTR Phase I grant, marking their fourth awarded project from the NIH.
-
![]()
WHIS Innovation Showcase Award
September 2024
Our CEO pitched and won the prestigious WHIS Innovation Showcase award for the Therapeutic, Diagnostic, and Medical Device category.
-
![]()
Reproductive Health Summit
February 2024
Our CEO presented on panel, “A New Age for Contraception? Opportunities to Improve the Benchmark Beyond Innovation” with the NIH, Gates Foundation, and Foreground Capital.
-
![]()
National Contraception Meeting
November 2023
Our CEO and Chief Medical Advisor presented updates on ongoing NIH-funded projects at the annual contraceptive meeting.
-
![]()
First Place Life Sciences Eddie Award
November 2023
Venova Technologies was awarded the first place 2023 Life Sciences Eddie Award (formerly New England Innovation Award).
-
![]()
LabCentral Ignite Award
September 2023
Venova Technologies was awarded a LabCentral Ignite Golden Ticket, providing mentorship, a cash prize, and lab space to underrepresented founders.
-
![]()
NIH/NICHD X01 Service Contract
February 2023
Venova Technologies received their second NICHD X01 Biological Testing Facility Service Request to perform in vitro barrier efficiency testing with human sperm.
-
![]()
$300K NIH STTR Phase I Grant
September 2022
Venova Technologies received their first SBIR/STTR Phase I grant, focused on completing their ex vivo study and developing their device for in vitro efficacy testing.
-
![]()
NIH/NICHD X01 Service Contract
June 2022
Venova Technologies received a NIH/NICHD X01 Biological Testing Facility Service Request to perform their first preclinical study in baboons.
INTERDISCIPLINARY APPROACH
Guided by Industry Knowledge and Research
MISSION-DRIVEN & IMPACT-ORIENTED
An Underserved Market with High Upside Potential
Offering a highly effective, long-acting, and side-effect-free birth control option will give hundreds of millions of women and girls more autonomy over their health, leading to healthier families and more prosperous societies.